Drug Cost Management Report

View more issues:

Articles in Dec, 2002 issue of Drug Cost Management Report

• Consumers and physicians are uncomfortable with the practice of prior drug authorization - Drug Cost Studies in Brief
• The FDA has issued a warning for users taking Bextra® , a COX-2 specific inhibitor - valdecoxib tablets - Clinical News in Brief
• Treatment guidelines for high-risk chest pain patients save lives, but these guidelines are not being routinely followed by physicians - Drug Cost Studies in Brief
• The state of Pennsylvania was advised not to pursue the Pharmacy Plus waiver, a Medicaid waiver program - State News in Brief
• The Regence Group has teamed up with Blue Cross Blue Shield of Michigan and Blue Care Network of Michigan - Drug Cost Strategies in Brief
• Genetic and cultural differences may be keeping minorities from receiving clinically appropriate prescription drugs - Clinical News in Brief
• Among diagnosed patients, awareness of direct-to-consumer advertising is high - DTC - Drug Cost Studies in Brief
• Medco Health Solutions has filed for a declaratory judgment claiming that West Virginia owes it approximately $2 million - Legal News in Brief
• Express Scripts is encouraging its clients and members to switch to the generic version of Prilosec as soon as it becomes available - omeprazole - Drug Cost Strategies in Brief
• The National Consumers League is urging the FDA not to switch new nonsedating antihistamines immediately to over-the-counter status - NCL - OTC - Clinical News in Brief
• One-third of Americans are using antibiotics inappropriately - Drug Cost Studies in Brief
• Pfizer will pay $49 million to federal and state authorities to resolve an investigation into grants made by Warner-Lambert to health plans and pharmacy benefit managers - Legal News in Brief
• PCN program racks up savings with clinically based physician education
• The FDA has approved Abilify™ tablets , a schizophrenia treatment by Bristol-Myers Squibb and Otsuka Pharmaceuticals - aripiprazole - Product News in Brief
• The majority of Maryland residents and the Maryland Health Advocacy Alliance are opposed to a preferred drug list for the state's Medicaid program - MHAA - State News in Brief
• Industry responds to ambiguous government guidelines
• Nearly 24 million Americans are affected by chronic obstructive pulmonary disease , usually caused by smoking - COPD - Clinical News in Brief
• Coming in January
• The ABCs of PBMs
  by Chris Nee
• Schering-Plough's Claritin has won FDA approval to be marketed over-the-counter - Product News in Brief
• First Health Group Corp. reported record revenue of $204.9 million, and record income of $33.7 million - NASDAQ:FHCC - Company News in Brief
• PBMI surveys employers on PBM fees, rebates, benefit structure
• Strattera , just approved by the FDA, is a new treatment for attention deficit hyperactivity disorder from Eli Lilly - atomexetine - ADHD - Product News in Brief
• NMHCRX reported $147.4 million in revenue - Company News in Brief